SCM
ARRY

Segantii Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Segantii Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,000
Closed -$9K – 354
2017
Q1 		$9K Buy
+1,000
New +$10.6K ﹤0.01% 369

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Segantii Capital Management's ARRY Position: Q2 2017 in Review

Segantii Capital Management sold out of Array Biopharma Inc (ARRY) in Q2 2017, closing a stake of 1,000 shares — an estimated $9K sold.

Segantii Capital Management first reported a position in ARRY in Q1 2017 and held it in 1 quarter. The position peaked at $9K in Q1 2017. 182 funds tracked by Wall St. Rank hold ARRY as of Q2 2017.

  • Segantii Capital Management reported no remaining Array Biopharma Inc position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 1,000 Array Biopharma Inc shares in Q2 2017, an estimated $9K.
  • Segantii Capital Management first reported a position in Array Biopharma Inc in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Array Biopharma Inc position peaked at $9K in Q1 2017.
  • 182 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.